This study builds on previous research, suggesting that clonal heterogeneity may contribute to the clinical patterns of acquired resistance to targeted therapies in various cancers, including gastrointestinal stromal tumors, chronic myeloid leukemia, and EGFR-mutant non-small cell lung cancer (NSCLC).25 This evidence concerns the gene EGFR and non-small cell lung carcinoma.